Roche fails in trial of Gazyva for untreated diffuse large B-cell lymphoma

19 July 2016

Swiss pharma giant Roche's (ROG: SIX) Gazyva (obinutuzumab) has failed to meet the primary endpoint of a Phase III study in people with previously untreated diffuse large B-cell lymphoma (DLBCL).

Gazyva, which is known as Gazyvaro in Europe, was tested in the GOYA study with CHOP chemotherapy in people with previously DLBCL in comparison with Roche’s approved medicine, MabThera/ Rituxan (rituximab) with chemotherapy.

It failed to reduce the risk of disease worsening or death, known as progression free survival (PFS), in comparison with the existing therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK